Louisville, Colo.’s Medivance, a maker of thermal-cooling systems for hospitals, raised $23 million in a fourth funding round. Investors included Cross Atlantic Partners, Camden Partners, Skyline Ventures, Partisan Management and MDY Healthcare. The company said a “major institutional investor” led the round.
Medivance makes and sells a patient-cooling system it calls the Arctic Sun, which can be used to lower the body temperature of patients with high fevers or who are otherwise at risk of organ or tissue damage that could be prevented by inducing a state of controlled hypothermia. The non-invasive system consists of cooling pads that are placed on a patient’s torso and limbs and a control unit.
According to VentureWire (subscription required), several companies are interested in the cooling market:
Tags: body-cooling, co:Medivance, deal, inv:Camden-Partners, inv:Cross-Atlantic-Partners, inv:MDY-Healthcare, inv:Partisan-Management, inv:Skyline-VenturesBody cooling has attracted considerable attention from entrepreneurs and VCs, as companies like QuickCool AB, BeneChill Inc., Radiant Medical Inc. and Alsius Corp. are tackling the same market. Norman Weldon, the other Partisan managing director, said that a good reason for Medivance’s success to date is that unlike some of its competiton, its device is non-invasive. “We came up with an approach that has had a very strong safety profile,” he said.
One Comment
-
Mark Wendman said:
I wrote the above linked blog post about Advances in Resuscitation Science (revival from [some] Heart Attacks etc), after a recent piece in Newsweek covering Dr. Lance Becker’s focus on using cooling and reduction in oxygen to inhibit the mitochondrial induced death switch as one might call it, increasing patient survival rates significantly, through better (presently unconventional) post cardiac trauma treatment.
Contrasted where presently the body is typically flooded with oxygen in present day misguided methods used to attempt patient revival, Dr. Lance Becker is helping to publicize better methods to help increase patient survival rates from heart attack and more.
The linked article I cobbled together describes some of the overview succinctly, and has numerous links to journal articles, hospital protocols, and equipment suppliers for inducing therapeutic hypothermia.
http://mark-nano.blogspot.com/2007/05/advances-in-resuscitation-science.html
If you like that article, you might also like my overview of DNA therapy efforts to reverse Parkinson’s, pursued by Drs. Mike Kaplitt and Matt During of Neurologix, linked here
http://mark-nano.blogspot.com/2007/06/dr-michael-kaplitts-viral-dna-gene.html
